<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Addition and titration of basal insulin is usually effective in improving glycaemic control in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but fear of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> remains a barrier </plain></SENT>
<SENT sid="1" pm="."><plain>Ability to predict which patients might be at greatest risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> might facilitate individualization of treatment and improve safety </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to obtain information about clinical characteristics which might predict risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> during initiation of basal insulin </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patient-level data from 2251 participants in 11 studies in which insulin glargine was started and titrated using similar treat-to-target methods was pooled and analysed with logistic regression models </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Participants had mean age 58 years, <z:mp ids='MP_0002055'>diabetes</z:mp> duration 8.9 years, body mass index 31.0 and baseline A1c 8.8% </plain></SENT>
<SENT sid="5" pm="."><plain>They attained mean A1c 7.1% during 6 months of treatment with final mean glargine dosage 0.44 units/kg </plain></SENT>
<SENT sid="6" pm="."><plain>Symptomatic <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> occurred in 52%, <z:chebi fb="105" ids="17234">glucose</z:chebi>-confirmed <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (blood <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;50 mg/dl) in 17%, repeated <z:chebi fb="105" ids="17234">glucose</z:chebi>-confirmed events in 7% and severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in 1.5% </plain></SENT>
<SENT sid="7" pm="."><plain>Independent predictors of <z:chebi fb="105" ids="17234">glucose</z:chebi>-confirmed <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> were younger age, lower body mass index, use of a sulphonylurea in addition to <z:chebi fb="0" ids="6801">metformin</z:chebi>, lower attained A1c and lower dosage of glargine </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: These findings confirm low rates of clinically important <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> using this method, and suggest that higher risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> may be suspected when patients needing insulin are younger, less <z:mp ids='MP_0001261'>obese</z:mp> and taking <z:chebi fb="0" ids="6801">metformin</z:chebi> and a sulphonylurea, and especially when A1c levels ≤7.0% are attained with glargine dosage ≤0.4 units/kg </plain></SENT>
</text></document>